Tidal Investments LLC Decreases Stake in Sanofi (NASDAQ:SNY)

Tidal Investments LLC reduced its position in Sanofi (NASDAQ:SNY - Free Report) by 65.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,741 shares of the company's stock after selling 9,057 shares during the quarter. Tidal Investments LLC's holdings in Sanofi were worth $229,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC grew its position in Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock valued at $261,000 after acquiring an additional 1,869 shares during the last quarter. Synergy Asset Management LLC bought a new position in shares of Sanofi during the 4th quarter valued at $25,000. OLD National Bancorp IN raised its position in Sanofi by 12.9% in the 4th quarter. OLD National Bancorp IN now owns 24,373 shares of the company's stock worth $1,176,000 after purchasing an additional 2,790 shares during the period. Cibc World Market Inc. lifted its stake in Sanofi by 3.4% in the fourth quarter. Cibc World Market Inc. now owns 315,888 shares of the company's stock worth $15,235,000 after purchasing an additional 10,328 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Sanofi by 13.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 63,845 shares of the company's stock worth $3,079,000 after buying an additional 7,615 shares during the period. 14.04% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on SNY. BNP Paribas began coverage on Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target on the stock. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Finally, The Goldman Sachs Group assumed coverage on shares of Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 price target for the company. Three analysts have rated the stock with a hold rating, two have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $63.33.

Sanofi Stock Up 1.1%

NASDAQ:SNY traded up $0.53 during mid-day trading on Wednesday, hitting $49.72. 416,410 shares of the company's stock were exchanged, compared to its average volume of 2,400,772. Sanofi has a one year low of $45.80 and a one year high of $60.12. The business has a fifty day moving average price of $52.03 and a 200 day moving average price of $51.94. The company has a market cap of $121.93 billion, a PE ratio of 19.96, a P/E/G ratio of 1.01 and a beta of 0.55. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The business had revenue of $10.41 billion during the quarter, compared to analysts' expectations of $9.79 billion. During the same quarter in the previous year, the business earned $1.78 earnings per share. The firm's quarterly revenue was down 11.0% compared to the same quarter last year. Equities analysts predict that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be issued a $2.0369 dividend. The ex-dividend date is Friday, May 9th. This is a boost from Sanofi's previous annual dividend of $1.48. This represents a yield of 3.1%. Sanofi's payout ratio is 57.14%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.